Finland-based Biotie Therapies (Nasdaq OMX: BTH1V), which is focused on neurodegenerative and psychiatric disorders, has completed further review of its pipeline.
The company published a review in September which highlighted the approval and launch of Selincro (nalmefene) in Europe by Denmark’s Lundbeck (LUN: CO) and the exercise by Belgium’s UCB (Euronext Brussels: UCB) of its license for tozadenant (SYN115), for which Biotie received a $20 million milestone.
Progressing SYN120
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze